All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The (pro)renin receptor ((P)RR) consists of 350 amino acids with a single transmembrane domain and binds preferentially to renin and prorenin \[[@pone.0233312.ref001]\]. The binding of prorenin to the extracellular domain of the (P)RR induces non-proteolytic renin activation \[[@pone.0233312.ref002]\], which accelerates the conversion of angiotensinogen to angiotensin (Ang) I. This process plays a key role in the regulation of the tissue renin-angiotensin system (RAS) \[[@pone.0233312.ref001]\]. (P)RR is cleaved by processing enzymes to generate soluble (P)RR (s(P)RR), which is secreted into the extracellular space and found in blood. These findings suggest that s(P)RR can serve as a biomarker reflecting the status of the tissue RAS and activity of (P)RR \[[@pone.0233312.ref003], [@pone.0233312.ref004]\].

Hemodialysis (HD) patients have a poor prognosis due to an increased prevalence of cardiovascular disease (CVD) \[[@pone.0233312.ref005], [@pone.0233312.ref006]\]. It has been reported that patients with heart failure had significantly higher plasma s(P)RR levels than control subjects \[[@pone.0233312.ref007]\]. We have previously reported that serum s(P)RR level is associated with arteriosclerosis, independent of other risk factors in HD patients \[[@pone.0233312.ref008]\]. These data prompted us to hypothesize that blood s(P)RR level could be associated with progression of CVD. However, it remains undermined if serum s(P)RR level is associated with the changes in indices of cardiovascular dysfunction. On the basis of these background findings, the present study aimed to investigate the relationship between serum s(P)RR level and changes in background factors including cardiac function and atherogenic factors.

Materials and methods {#sec002}
=====================

Study subjects {#sec003}
--------------

The participants were outpatients on maintenance HD at Kadoma Keijinnkai Clinic, Neyagawa Keijinnkai Clinic, and Moriguchi Keijinnkai Clinic in Osaka Prefecture, Japan. All three clinics are affiliated with Moriguchi Keijinkai Hospital, Osaka, Japan. This study was approved by the ethical committee of Tokyo Women's Medical University (approval number: 2703), and all patients were enrolled after obtaining written informed consent. A total of 258 maintenance HD patients who could be followed up for 12 months were recruited consecutively between March and May 2013.

Background factors {#sec004}
------------------

At the start of this study, we collected information on the study population, including age, sex, body mass index (BMI), primary disease (diabetic or not), duration of HD, smoking status, selected medication, CTR, and Kt/V. BMI was calculated as follows: BMI = *post-dialysis value of body weight (kg) / \[height (m)\]*^2^} × 100. Post-dialysis cardiothoracic ratio (CTR) values were obtained on the first dialysis day of the week. The Kt/V was calculated on the 1st dialysis day of the week using the following equation, the formula of Daugirdas \[[@pone.0233312.ref009]\]: Kt/V = ---*Ln \[post-dialysis value of BUN / pre-dialysis value of BUN---0*.*008 x dialysis time\] + (4--3*.*5 x post-dialysis value of BUN / pre-dialysis value of BUN) x amount of drainage / post-dialysis body weight}*

Blood examinations {#sec005}
------------------

Non-fasting blood samples were taken while patients were lying in bed in a supine position after at least 15 minutes of rest on the first dialysis day of the week. The following pre-dialysis parameters were measured: hemoglobin (Hb), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), albumin-corrected calcium (Ca), inorganic phosphorus (IP), intact parathyroid hormone (Intact-PTH), creatinine (Cre), uric acid (UA), C-reactive protein (CRP), and albumin (Alb) levels.

The following post-dialysis values were measured by conventional methods at an external testing laboratory (Kishimoto, Inc., Tomakomai City, Japan):human atrial natriuretic peptide (hANP), a marker of body fluid volume \[[@pone.0233312.ref010]--[@pone.0233312.ref012]\] and brain natriuretic peptide (BNP), a marker of left ventricular dysfunction \[[@pone.0233312.ref013]\].

Pre-dialysis serum s(P)RR levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Takara Bio Inc., Otsu City, Japan) consisting of a solid-phase sandwich ELISA with antibodies highly specific for each protein \[[@pone.0233312.ref014]\].

Physiological function tests {#sec006}
----------------------------

### Echocardiography {#sec007}

Echocardiography was performed on a non-dialysis day as previously described using the Vivid S6 System (GE Healthcare, Milwaukee, WI, USA), and cardiac functions as follows were estimated: 1) left ventricular ejection fraction (LVEF), a marker of contractile activity; 2) interventricular septum thickness (IVST), posterior LV wall thickness (PWT), and left ventricular mass index (LVMI), markers of cardiac hypertrophy \[[@pone.0233312.ref015]\]; and 3) E over e-prime (E/e') and deceleration time (Dec-T), markers of left ventricular diastolic function \[[@pone.0233312.ref016]\].

*Ankle-brachial index and brachial ankle pulse wave velocity (baPWV)*. The ankle-brachial index (ABI) values (average and lower values) and baPWV values (average and higher values) were measured on a non-dialysis day using a volume-plethysmographic apparatus PWV/ABI (Omron Healthcare Co., Ltd., Kyoto, Japan) following previously described methods \[[@pone.0233312.ref017]\]. BaPWV cannot be estimated properly when the ABI is less than 0.9 because arterial occlusion retards baPWV \[[@pone.0233312.ref018], [@pone.0233312.ref019]\]. Therefore, patients with ABI \<0.9 were excluded from the analysis of baPWV.

Computed tomography (CT) {#sec008}
------------------------

Body fat distribution was determined using CT imaging on a non-dialysis day with the use of a 64-row multislice CT scanner (Aquilion 64; Toshiba, Tokyo, Japan). The subcutaneous fat area (SFA) and visceral fat area (VFA) were measured at the level of the umbilicus using Ziostation 2 software (Ziosoft, Tokyo, Japan).

Study protocols {#sec009}
---------------

Pre-dialysis serum s(P)RR levels on the first dialysis day of the week were measured at the start of the study. The patients were divided into two groups (higher and lower groups) according to serum s(P)RR values, and we compared the groups in terms of background factors, blood data, physiological function data, and CT data. Patients were followed up for 12 months or until death from any cause. We compared baseline characteristics in the survival and death groups. In the survival group, we compared background factors, blood data, physiological function data, and CT data at baseline and after 12 months, and the changes in these values (Δ) were compared in the higher and lower serum s(P)RR groups. Finally, we examined the association between serum s(P)RR level and Δ BNP.

Statistical analyses {#sec010}
--------------------

For all continuous variables, parametric variables and non-parametric variables were expressed as mean ± SD and median with interquartile ranges (25th and 75th percentiles), respectively. Intergroup comparisons of parameters were performed using a Wilcoxon signed-rank test or Mann-Whitney U test. Categorical variables were presented as the number of patients and compared using a chi-square test. We calculated the Spearman's rank correlation coefficient between Δ BNP and background factors, blood data, physiological function data, and CT data. Multiple regression analyses were performed using factors that showed significant correlation with Δ BNP as independent variables. The level of significance was defined as P\<0.05. All analyses were performed using Bell Curve for Excel (Social Survey Research Information Co. Ltd., Tokyo, Japan).

Results {#sec011}
=======

Characteristics of the study patients at baseline {#sec012}
-------------------------------------------------

The median serum s(P)RR value at baseline was 29.8 ng/ml. [Table 1](#pone.0233312.t001){ref-type="table"} details the baseline characteristics of the study patients in the two groups (higher and lower serum s(P)RR groups) and includes background factors, blood data, physiological function data, and CT data. The number of patients with measurements of ABI and baPWV was 247. Forty-four of these patients showed an ABI of \<0.9. As a result, a total of 203 patients were included in the baPWV analysis. CTR, Hb, TG, and CRP levels were significantly higher, and IVST was significantly lower in the higher serum s(P)RR group than in the lower serum s(P)RR group. With respect to antihypertensive treatment, the ratio of patients taking RAS-inhibitors (RAS-Is), such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors, was significantly higher in the lower serum s(P)RR group (83.7%) than in the higher serum s(P)RR group (69.0%). Primary disease (diabetic or not) was not significantly different between the 2 groups. In addition, neither BMI nor Kt/V was significantly different between the 2 groups, suggesting that hemodialysis parameters may not have strong influences on the serum s(P)RR levels.

10.1371/journal.pone.0233312.t001

###### Comparison of characteristics of the study subjects at baseline between higher and lower groups of serum s(P)RR concentration.
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                                                  higher group              lower group               P
  ----------------------------------------------- ------------------------- ------------------------- ---------
  **Background factors**                                                                              
      Age (y.o.)                                  72 (62--77)               68 (59--74)               0.070
      Gender (male/female)                        71/58                     75/54                     0.615
      Body mass index (kg/m^2^)                   21.8 (19.9--24)           21.6 (19.4--24.2)         0.549
      Primary disease (DM/non DM)                 55/74                     68/61                     0.105
      Duration of hemodialysis therapy (months)   48 (24--84)               48 (24--72)               0.788
      Smoking history (yes/no)                    55/74                     60/69                     0.531
      Medications (yes/no)                                                                            
          RAS-I                                   89 / 40                   108 / 21                  0.005
          β-blocker                               44 / 85                   54 / 75                   0.217
          CCB                                     90 / 39                   100 / 29                  0.188
      CTR (%)                                     53.0 (49.4--55.4)         51.7 ± 5.2                0.040
      Kt/V                                        1.36 ± 0.26               1.34 ± 0.22               0.313
  **Blood tests**                                                                                     
      Hemoglobin (g/dl)                           10.9 ± 1.0                10.7 (10.2--11.2)         0.036
      HDL cholesterol (mg/dl)                     46.0 (38.0--55.0)         45.0 (36.0--55.0)         0.632
      LDL cholesterol (mg/dl)                     91.3 ± 30.5               83.0 (64.0--103.0)        0.203
      Triglyceride (mg/dl)                        96.0 (68.0--136.0)        81.0 (55.0--113.0)        0.004
      Calcium (mg/dl)                             8.8 (8.5--9.2)            8.8 (8.6--9.1)            0.970
      Inorganic phosphorus (mg/dl)                5.4 (4.4--6.0)            5.1 ± 1.1                 0.064
      Intact-Parathyroid hormone (pg/ml)          139.0 (84.0--185.0)       123.0 (76.0--176.0)       0.305
      Creatinine (mg/dl)                          9.5 ± 2.5                 9.7 ± 2.6                 0.478
      Uric acid (mg/dl)                           7.3 ± 1.4                 7.0 ± 1.3                 0.053
      CRP (mg/dl)                                 0.13 (0.05--0.49)         0.07 (0.05--0.19)         \<0.001
      Albumin (g/dl)                              3.7 ± 0.3                 3.7 (3.5--3.9)            0.422
      hANP (pg/ml)                                48.2 (28.2--78.2)         46.7 (31.5--74.9)         0.866
      BNP (pg/ml)                                 136.6 (76.4--287.4)       148.9 (74.9--244.5)       0.974
  **Physical function tests**                                                                         
      Echocardiography                                                                                
          LVEF (%)                                67.6 (62.8--72.1)         67.2 (63.5--71.5)         0.361
  IVST (mm)                                       12.0 (11.1--13.5)         12.4 (11.4--13.5)         0.036
  PWT (mm)                                        12.0 (11.0--13.0)         12.0 (11.3--13.1)         0.090
  LVMI (g/m^2^)                                   171.1 (144.9--202.7)      180.5 ± 50.0              0.202
  E/e\'                                           18.0 (14.0--22.1)         18.8 (14.9--22.2)         0.404
  Dec-T                                           229.0 (199.8--264.1)      231.7 ± 54.1              0.817
      ABI                                                                                             
          ≥0.9 / \<0.9                            96/25                     107/19                    0.252
          average value                           1.15 (1.05--1.23)         1.17 (1.07--1.24)         0.378
          lower value                             1.13 (0.95--1.20)         1.13 (1.00--1.21)         0.776
      baPWV (cm/s)                                                                                    
          average value                           1794.8 (1568.4--2065.9)   1853.5 (1606.8--2176.8)   0.719
          higher value                            1907.0 (1639.5--2165.8)   1921.0 (1641.5--2234.0)   0.774
  **Abdominal CT**                                                                                    
      Subcutaneous fat area (cm^2^)               110.9 (72.2--171.2)       105.5 (59.8--155.6)       0.105
      Visceral fat area (cm^2^)                   79.1 (47.7--119.3)        69.4 (33.1--112.1)        0.097

DM, diabetes mellitus; RAS-I, renin-angiotensin system inhibitor; CCB, calcium channel blocker; CTR, cardiothoracic ratio; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; CRP, C-reactive protein; hANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; IVST, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVMI, left ventricular mass index; E/e\', E over e-prime; Dec-T, deceleration time; ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity

Comparison of study patient characteristics at baseline in the survival and death groups {#sec013}
----------------------------------------------------------------------------------------

During the 12-month follow-up period, one patient received a renal transplant and 24 deaths (9.3%) were recorded. There were 14 cardiovascular deaths (5.4%), including one due to acute myocardial infarction, six to congestive heart failure, five to lethal arrhythmia, and two to sudden unexpected deaths. Ten non-cardiovascular deaths (3.9%) were recorded, including five because of infectious diseases; two, cachexia; and three, cancer. The 1-year survival rate was 90.7%. [Table 2](#pone.0233312.t002){ref-type="table"} details the comparison of study patient characteristics at baseline in the survival and death groups. Age, male sex, CTR, CRP, hANP, BNP, E/e', and low ABI (\<0.9) were significantly higher, and BMI, HDL-C, Cre, Alb, and LVEF were significantly lower in the death group than in the survival group. No significant differences in serum s(P)RR levels were noted between patients in the death group (29.8 ± 6.1 ng/ml) and the survival group (29.9 \[26.6--34.1\] ng/ml). No significant differences in primary disease (DM/no DM) was noted between in the survival and death groups. With respect to antihypertensive treatment, the ratio of patients taking RAS-Is and calcium channel blockers (CCBs) were significantly higher in the survival group (79.4% and 77.3%, respectively) than the death group (45.8% and 41.7%, respectively).

10.1371/journal.pone.0233312.t002

###### Comparison of characteristics of the study subjects at baseline between in survival and death groups.

![](pone.0233312.t002){#pone.0233312.t002g}

                                                  survival                  death                  P
  ----------------------------------------------- ------------------------- ---------------------- ---------
  **Background factors**                                                                           
      n                                           233                       24                     
      Age (y.o.)                                  68 (60--76)               77 ± 10                \<0.001
      Gender (male/female)                        129 / 104                 16 / 8                 0.002
      Body mass index (kg/m^2^)                   21.8 (19.8--24.1)         20.5 ± 3.6             0.017
      Primary disease (DM/non DM)                 107 /126                  16 / 8                 0.053
      Duration of hemodialysis therapy (months)   48 (24--84)               39 (24--68)            0.426
      Smoking history (yes/no)                    106 / 127                 8 /16                  0.254
      Medications (yes/no)                                                                         
          RAS-I (yes/no)                          185 / 48                  11 / 13                \<0.001
          β-blocker (yes/no)                      90 / 143                  8 / 16                 0.611
          CCB (yes/no)                            180 / 53                  10 / 14                \<0.001
      CTR (%)                                     51.1 (49.0--55.0)         56.0 ± 5.8             \<0.001
      Kt/V                                        1.35±0.24                 1.34±0.19              0.421
  **Blood tests**                                                                                  
      s(P)RR (ng/ml)                              29.9 (26.6--34.1)         29.8 ± 6.1             0.795
      Hemoglobin (g/dl)                           10.8 (10.3--11.4)         10.6 ± 1.2             0.403
      HDL cholesterol (mg/dl)                     46.0 (37.0--56.0)         40.8 ± 7.7             0.034
      LDL cholesterol (mg/dl)                     85.0 (66.0--108.0)        90.7 ± 28.7            0.615
      Triglyceride (mg/dl)                        88.0 (59.0--126.0)        97.7 ± 45.7            0.906
      Calcium (mg/dl)                             8.8 (8.5--9.2)            8.8 ± 0.5              0.848
      Inorganic phosphorus (mg/dl)                5.1 (4.3--5.8)            5.4 (4.4--6.2)         0.641
      Intact-Parathyroid hormone (pg/ml)          129.0 (82.0--176.0)       165.5 ± 102.5          0.385
      Creatinine (mg/dl)                          9.7 ± 2.6                 8.3 ± 1.8              0.002
      Uric acid (mg/dl)                           7.2 ± 1.3                 7.0 ± 1.4              0.567
      CRP (mg/dl)                                 0.09 (0.05--0.23)         0.53 (0.22--1.06)      \<0.001
      Albumin (g/dl)                              3.7 (3.5--3.9)            3.4 ± 0.4              \<0.001
      hANP (pg/ml)                                45.6 (28.7--71.7)         68.6 (54.9--167.2)     \<0.001
      BNP (pg/ml)                                 136.4 (73.8--242.9)       275.9 (185.0--961.6)   \<0.001
  **Physical function tests**                                                                      
      Echocardiography                                                                             
          LVEF (%)                                67.6 (62.8--72.1)         61.1 (41.9--65.2)      0.001
  IVST (mm)                                       12.0 (11.1--13.5)         12.3 ±1.8              0.881
  PWT (mm)                                        12.0 (11.0--13.0)         11.9 (11.1--12.8)      0.752
  LVMI (g/m^2^)                                   171.1 (144.9--202.7)      191.5 ± 44.7           0.092
  E/e\'                                           18.0 (14.0--22.1)         24.2 ± 12.1            0.015
  Dec-T                                           229.0 (199.8--264.1)      215.3 ± 77.1           0.068
      ABI                                                                                          
          ≥0.9 / \<0.9                            187 / 40                  16 / 7                 \<0.001
          average value                           1.16 (1.06--1.23)         1.12 ± 0.26            0.968
          lower value                             1.13 (0.98--1.21)         1.11 (0.94--1.26)      0.876
      baPWV (cm/s)                                                                                 
          average value                           1835.0 (1597.0--2156.3)   1912.5 ± 421.5         0.565
          higher value                            1903.5 (1635.0--2208.0)   2018.3 ± 407.6         0.295
  **Abdominal CT**                                                                                 
      Subcutaneous fat area (cm^2^)               108.7 (69.7--162.7)       92.3 ± 71.5            0.050
      Visceral fat area (cm^2^)                   77.1 (41.9--120.4)        61.0 (39.2--79.4)      0.075

DM, diabetes mellitus; RAS-I, renin-angiotensin system inhibitor; CCB, calcium channel blocker; CTR, cardiothoracic ratio; s(P)RR, soluble (pro)renin receptor; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; CRP, C-reactive protein; hANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; IVST, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVMI, left ventricular mass index; E/e\', E over e-prime; Dec-T, deceleration time; ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity

Characteristics of the study patients at baseline and after 12 months in the survival group {#sec014}
-------------------------------------------------------------------------------------------

In patients who survived, CTR, Ca, CRP, hANP, and BNP values, IVST, PWT, LVMI, Dec-T, average ABI, lower ABI, average baPWV, and higher baPWV were significantly higher and LVEF, E/e', SFA, and VFA were significantly lower after 12 months than at baseline ([Table 3](#pone.0233312.t003){ref-type="table"}). Δ hANP and Δ BNP values and Δ IVST were significantly greater in the higher serum s(P)RR group than in the lower group ([Table 4](#pone.0233312.t004){ref-type="table"}, [Fig 1](#pone.0233312.g001){ref-type="fig"}). By contrast, Δ Hb, Δ Cre, and UA values were significantly lower in the higher serum s(P)RR group than in the lower group ([Table 4](#pone.0233312.t004){ref-type="table"}).

![Box plots comparing changes (Δ) in hANP, BNP, and IVST in the higher serum s(P)RR and lower serum s(P)RR groups.\
Δ, changes during 12 months; hANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide; IVST, intraventricular septum thickness; s(P)RR, soluble (pro)renin receptor.](pone.0233312.g001){#pone.0233312.g001}

10.1371/journal.pone.0233312.t003

###### Characteristics of the study subjects at baseline and after 12 months in patients who survived.
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                                           baseline                  after 12 months           P          Δ
  ---------------------------------------- ------------------------- ------------------------- ---------- ----------------------
  **Background factors**                                                                                  
      Body mass index (kg/m^2^)            21.8 (19.8--24.1)         21.7 (19.6--24.3)         0.074      0.0 (-0.6--0.5)
      CTR (%)                              51.1 (49.0--55.0)         53.5 (49.5--57.7)         \< 0.001   1.8 (-0.5--4.0)
  **Blood tests**                                                                                         
      Hemoglobin (g/dl)                    10.8 (10.3--11.4)         10.9 (10.3--11.5)         0.151      0.2 (-0.8--0.9)
      HDL cholesterol (mg/dl)              46.0 (37.0--56.0)         46.0 (38.0--54.0)         0.250      0.0 (-5.0--4.0)
      LDL cholesterol (mg/dl)              85.0 (66.0--108.0)        87.6 ± 28.6               0.400      0.0 (-13.0--12.8)
      Triglyceride (mg/dl)                 88.0 (59.0--126.0)        84.0 (63.0--121.0)        0.278      0.0 (-23.0--22.0)
      Calcium (mg/dl)                      8.8 (8.5--9.2)            9.0 ± 0.5                 \<0.001    0.1 (-0.1--0.5)
      Inorganic phosphorus (mg/dl)         5.1 (4.3--5.8)            5.1 (4.5--5.9)            0.100      0.1 (-0.8--1.0)
      Intact-Parathyroid hormone (pg/ml)   129.0 (82.0--176.0)       132.0 (85.0--184.0)       0.375      2.0 (-44.0--52.0)
      Creatinine (mg/dl)                   9.7 ± 2.6                 10.1 ± 2.7                0.076      0.3 (-0.5--1.3)
      Uric acid (mg/dl)                    7.2 ± 1.3                 7.1 (6.3--7.9)            0.066      -0.1 (-0.8--0.6)
      CRP (mg/dl)                          0.09 (0.05--0.23)         0.10 (0.05--0.28)         0.040      0.0 (0.0--0.1)
      Albumin (g/dl)                       3.7 (3.5--3.9)            3.7 (3.5--3.9)            0.093      0.0 (-0.1--0.1)
      hANP (pg/ml)                         45.6 (28.7--71.7)         54.6 (33.4--76.0)         0.003      2.5 (-11.7--23.4)
      BNP (pg/ml)                          136.4 (73.8--242.9)       184.7 (90.4--351.6)       \<0.001    5.5 (-58.2--80.7)
  **Physical function tests**                                                                             
      Echocardiography                                                                                    
          LVEF (%)                         67.2 (62.0--71.7)         65.1 (59.5--71.1)         \<0.001    -1.4 (-6.7--3.8)
  IVST (mm)                                12.0 (11.2--13.5)         12.4 (11.5--13.8)         \<0.001    0.2 (-0.7--1.5)
  PWT (mm)                                 12.0 (11.1--13.0)         12.2 (11.3--13.5)         \<0.001    0.3 ± 1.4
  LVMI (g/m^2^)                            172.7 (146.6--204.7)      176.9 (152.1--219.2)      \<0.001    1.8 (-20.1--37.7)
  E/e\'                                    18.6 (14.0--22.6)         18.1 (14.5--23.4)         \<0.001    0.5 (-2.3--4.1)
  Dec-T                                    226.9 (196.1--264.1)      231.0 (193.5--260.4)      0.003      7.9 (-34.4--39.2)
      ABI                                                                                                 
          average value                    1.16 (1.06--1.23)         1.18 (1.05--1.25)         0.005      -0.1 (-0.1--0.1)
          lower value                      1.13 (0.98--1.21)         1.14 (0.97--1.22)         0.001      0.0 (-0.1--0.1)
      baPWV (cm/s)                                                                                        
          average value                    1835.0 (1597.0--2156.3)   1882.0 (1629.9--2124.3)   \<0.001    41.0 (-144.6--207.9)
          higher value                     1903.5 (1635.0--2208.0)   1902.0 (1656.0--2207.0)   \<0.001    51.5 (-131.5--225.8)
  **Abdominal CT**                                                                                        
      Subcutaneous fat area (cm^2^)        108.7 (69.7--162.7)       101.0 (63.1--161.0)       \<0.001    -4.3 (-22.6--12.8)
      Visceral fat area (cm^2^)            77.1 (41.9--120.4)        74.7 (34.5--114.4)        0.002      -3.7 (-15.9--10.4)

Δ, changes during 12 months; CTR, cardiothoracic ratio; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; CRP, C-reactive protein; hANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; IVST, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVMI, left ventricular mass index; E/e\', E over e-prime; Dec-T, deceleration time; ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity

10.1371/journal.pone.0233312.t004

###### Comparison of changes (Δ) in each parameter between higher and lower groups of serum s(P)RR concentration in patients who survived.
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                                           higher group           lower group            P
  ---------------------------------------- ---------------------- ---------------------- ---------
  **Background factors**                                                                 
      Body mass index (kg/m^2^)            -0.1 (-0.6--0.4)       0.0 (-0.6--0.5)        0.656
      CTR (%)                              2.1 (0.1--4.3)         1.3 (-0.8--3.4)        0.098
  **Blood tests**                                                                        
      Hemoglobin (g/dl)                    -0.2 ± 1.5             0.3 ± 1.1              \<0.001
      HDL cholesterol (mg/dl)              -1.0 ± 9.0             1.0 (-3.0--5.0)        0.124
      LDL cholesterol (mg/dl)              -2.0 (-15.0--11.5)     1.3 ± 19.2             0.151
      Triglyceride (mg/dl)                 -3.0 (-28.5--19.0)     4.0 (-19.3--24.0)      0.099
      Calcium (mg/dl)                      0.2 (-0.1--0.5)        0.1 (-0.2--0.4)        0.134
      Inorganic phosphorus (mg/dl)         -0.1 ± 1.7             0.2 ± 1.2              0.052
      Intact-Parathyroid hormone (pg/ml)   -1.0 (-46.0--52.0)     2.0 (-41.8--50.0)      0.957
      Creatinine (mg/dl)                   0.0 ± 1.5              0.6 (-0.2--1.3)        0.003
      Uric acid (mg/dl)                    -0.3 (-1.0--0.5)       0.1 ± 0.9              0.016
      CRP (mg/dl)                          0.00 (-0.07--0.14)     0.00 (-0.02--0.05)     0.964
      Albumin (g/dl)                       -0.1 (-0.2--0.1)       0.0 (-0.1--0.1)        0.093
      hANP (pg/ml)                         6.4 (-9.3--28.0)       -3.0 (-15.7--13.4)     0.008
      BNP (pg/ml)                          20.0 (-34.9--113.6)    -4.7 (-73.3--50.8)     0.035
  **Physical function tests**                                                            
      Echocardiography                                                                   
  LVEF (%)                                 -1.9 (-7.2--3.6)       -1.2 (-5.5--3.7)       0.509
  IVST (mm)                                0.8 ± 1.8              0.1 ± 1.4              0.005
  PWT (mm)                                 0.5 ± 1.5              0.2 ± 1.3              0.130
  LVMI (g/m^2^)                            7.1 (-18.5--37.7)      -1.1 (-20.8--36.8)     0.567
  E/e\'                                    0.8 (-1.7--4.3)        0.4 ± 4.7              0.295
  DecT                                     8.8 (-37.9--37.9)      4.4 ± 57.3             0.786
      ABI                                                                                
          average value                    0.01 (-0.07--0.05)     -0.01 (-0.07--0.04)    0.768
          lower value                      -0.01 (-0.07--0.05)    0.01 (-0.08--0.06)     0.949
      baPWV (cm/s)                                                                       
          average value                    50.5 (-118.4--236.0)   36.0 (-144.9--195.2)   0.997
          higher value                     45.5 (-159.8--243.8)   52.0 (-124.5--203.0)   0.740
  **Abdominal CT**                                                                       
      Subcutaneous fat area (cm^2^)        -2.4 (-28.8--14.7)     -6.5 (-21.8--9.6)      0.538
      Visceral fat area (cm^2^)            -6.1 ± 28.5            -3.0 (-11.6--10.9)     0.121

Δ, changes during 12 months; CTR, cardiothoracic ratio; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; CRP, C-reactive protein; hANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; IVST, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVMI, left ventricular mass index; E/e\', E over e-prime; Dec-T, deceleration time; ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity

Relationship between Δ BNP and background factors in the survival group {#sec015}
-----------------------------------------------------------------------

In patients who survived, LDL-C and TG levels were significantly and positively correlated, and hANP and BNP levels were significantly and negatively correlated with Δ BNP ([Table 5](#pone.0233312.t005){ref-type="table"}). The ratio of patients taking RAS-Is, β-blockers, and CCBs did not show significant relationship with ΔBNP. Serum s(P)RR level was not associated with ΔBNP level ([Table 5](#pone.0233312.t005){ref-type="table"}). On the other hand, when the subjects were divided into the higher and lower s(P)RR groups, ΔBNP was significantly higher in the higher s(P)RR group than in the lower s(P)RR group ([Fig 1](#pone.0233312.g001){ref-type="fig"}). Multiple regression analyses testing higher serum s(P)RR (≥29.8 ng/ml), LDL-C level, TG, hANP, and BNP as independent variables revealed that higher serum s(P)RR (≥29.8 ng/ml) correlated with Δ BNP, independent of other factors ([Table 6](#pone.0233312.t006){ref-type="table"}).

10.1371/journal.pone.0233312.t005

###### Single correlation analyses with ΔBNP in patients who survived.
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                                         ρ        P                                       ρ        P
  -------------------------------------- -------- --------- ----------------------------- -------- ---------
  **Background factors**                                    BNP                           -0.415   \<0.001
      Age                                -0.010   0.906     **Physical function tests**            
      Body mass index                    -0.006   0.946     Echocardiography                       
      Duration of hemodialysis therapy   0.045    0.585     LVEF                          0.026    0.774
      CTR                                -0.041   0.623     IVST                          0.008    0.920
  **Blood tests**                                           PWT                           -0.009   0.917
      s(P)RR                             0.132    0.109     LVMI                          -0.056   0.507
      Hemoglobin                         0.029    0.722     E/e\'                         0.022    0.796
      HDL cholesterol                    -0.052   0.528     Dec-T                         -0.733   0.383
      LDL cholesterol                    0.199    0.015     ABI                                    
      Triglyceride                       0.162    0.048     average value                 0.009    0.919
      Calcium                            -0.025   0.764     lower value                   0.033    0.697
      Inorganic phosphorus               -0.068   0.408     baPWV                                  
      Intact-Parathyroid hormone         0.129    0.118     average value                 0.104    0.258
      Creatinine                         -0.119   0.150     higher value                  0.119    0.194
      Uric acid                          0.003    0.971     **Abdominal CT**                       
      CRP                                0.028    0.737     Subcutaneous fat area         0.087    0.297
      Albumin                            0.014    0.866     Visceral fat area             0.060    0.471
      hANP                               -0.304   \<0.001                                          

Δ, changes during 12 months; BNP, brain natriuretic peptide; CTR, cardiothoracic ratio; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; CRP, C-reactive protein; hANP, human atrial natriuretic peptide; LVEF, left ventricular ejection fraction; IVST, interventricular septum thickness; PWT, posterior left ventricular wall thickness; LVMI, left ventricular mass index; E/e\', E over e-prime; Dec-T, deceleration time; ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity

10.1371/journal.pone.0233312.t006

###### Multiple regression analyses with ΔBNP in patients who survived.
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  Variables         ΔBNP                      
  ----------------- ------------------------- ---------
  s(P)RR            0.159                     0.042
  LDL cholesterol   \-                        \-
  Triglyceride      \-                        \-
  hANP              0.163                     0.057
  BNP               -0.611                    \<0.001
                    R^2^ = 0.133, P \<0.001   
                    for entire model          

Δ, changes during 12 months; BNP, brain natriuretic peptide; s(P)RR, soluble (pro)renin receptor; LDL cholesterol, low-density lipoprotein cholesterol; hANP, human atrial natriuretic peptide

Discussion {#sec016}
==========

The present study aimed to investigate the relationship between high serum s(P)RR level and changes in cardiac function and atherogenic factors and demonstrated three major findings. Firstly, some types of atherogenic factors and cardiac functions were significantly worse in the higher serum s(P)RR group than in the lower group. Secondly, in patients who survived, Δ hANP and Δ BNP levels, and Δ IVST were significantly greater in the higher serum s(P)RR group than in the lower group. Finally, in patients who survived, the association between high Δ BNP and higher serum s(P)RR was observed even after correction for other Δ BNP-related factors. These data suggest that an increased expression of (P)RR may be associated with a progression of heart failure in HD patients.

Serum s(P)RR levels {#sec017}
-------------------

It has been shown that basal blood s(P)RR levels differ among reports with a tendency of blood s(P)RR levels to be high in older subjects \[[@pone.0233312.ref004], [@pone.0233312.ref020]\], patients with heart failure \[[@pone.0233312.ref007]\], renal dysfunction \[[@pone.0233312.ref021]\], or Graves' disease \[[@pone.0233312.ref022]\], and pregnant women \[[@pone.0233312.ref023], [@pone.0233312.ref024]\]. The reason of the alterations of these values may be due to the differences of the disease and conditions of the subjects \[[@pone.0233312.ref024]\]. Our study subjects undergoing maintenance HD also showed high serum s(P)RR levels, which were significantly higher when compared with subjects with normal renal function \[[@pone.0233312.ref008]\]. Although the reason for this remains unclear, there are several possible explanations. First, elevated serum s(P)RR levels may reflect an increase in expression of (P)RR in the kidneys. Second, increased expression of (P)RR in other organs such as the heart and brain, where the expression levels of (P)RR are extremely high \[[@pone.0233312.ref001]\], may be the cause of elevated serum s(P)RR level. Third, elevated serum s(P)RR levels may be simply due to a decrease or loss of excretion from the kidney.

Comparison of characteristics of the study subjects at baseline between higher and lower groups of serum s(P)RR concentration {#sec018}
-----------------------------------------------------------------------------------------------------------------------------

We have previously reported that serum s(P)RR level was significantly higher in patients with ABI \<0.9 than in those with ABI ≥0.9, and this association was observed even after correction for atherogenic factors such as age, history of smoking, HbA1c, and LDL-C \[[@pone.0233312.ref008]\]. It was considered that high serum s(P)RR levels in HD patients may be associated with severe atherosclerosis of the lower limbs, independent of other risk factors, and that serum s(P)RR concentration could be used as a marker for atherosclerotic conditions in these patients \[[@pone.0233312.ref008]\].

The present study showed that atherogenic factors and markers of cardiac dysfunction were greater in the higher serum s(P)RR group than in the lower serum s(P)RR group ([Table 1](#pone.0233312.t001){ref-type="table"}) in accordance with our previous report \[[@pone.0233312.ref008]\]. All these findings raise the possibility that an increased expression of tissue RAS and/or elevated serum s(P)RR concentration may be associated with a progression of CVD.

In our study, the patients in the lower serum s(P)RR group took RAS-Is more frequently than those in the higher serum s(P)RR group ([Table 1](#pone.0233312.t001){ref-type="table"}). It has been reported that a significantly lower level of serum s(P)RR was observed in CKD patients treated with ARBs \[[@pone.0233312.ref021]\], consistent with our study.

Comparison of characteristics of the study subjects at baseline in between survival and death groups {#sec019}
----------------------------------------------------------------------------------------------------

There is a significant association among inflammatory state, atherosclerotic CVD, and malnutrition, which has been described as malnutrition, inflammation, and atherosclerosis (MIA) syndrome. The presence of MIA syndrome is strongly associated with mortality in pre-dialysis chronic kidney disease and dialysis populations \[[@pone.0233312.ref025]\]. In line with these reports, our study demonstrated that CRP level was significantly higher, and BMI, Cre, and Alb were significantly lower in the death group than in the survival group ([Table 2](#pone.0233312.t002){ref-type="table"}).

Manifestations of left ventricular disease are frequent and persistent, and are associated with high risks of heart failure and death in HD patients \[[@pone.0233312.ref026]\]. Heart failure was a strong, independent, adverse prognostic indicator in these patients \[[@pone.0233312.ref027]\]. In accordance with these findings, our study showed that CTR, hANP and BNP levels, and E/e' were significantly higher and LVEF was significantly lower in the death group than in the survival group ([Table 2](#pone.0233312.t002){ref-type="table"}), suggesting that the status of systolic and diastolic dysfunction and heart failure are related to increased risk of death in HD patients. In addition, it has been reported that HD patients have advanced atherosclerosis, which is causally related to poor prognosis \[[@pone.0233312.ref005], [@pone.0233312.ref006]\], and we have previously reported that serum s(P)RR level was associated with arteriosclerosis, independent of other risk factors in these patients \[[@pone.0233312.ref008]\]. Therefore, we had anticipated that high serum s(P)RR level may be associated with poor prognosis. However, unexpectedly, in the present study, no significant difference in serum s(P)RR level was noted between patients in the death group and the survival group. Although the reason for this result is unclear, it may be possible that a 1-year observation period, which we set to estimate the association between serum s(P)RR level and changes in background factors without losing many patients due to death, was too short to investigate the relationship between serum s(P)RR level and prognosis. We are planning to assess the prognostic value of serum s(P)RR level after a longer follow-up period.

In this study, the ratio of patients taking RAS-Is and CCBs was higher in the survival group than in the death group ([Table 2](#pone.0233312.t002){ref-type="table"}). Because our sample size was relatively small and most patients were taking both RAS-Is and CCBs, statistical group comparisons between patients with and without antihypertensive drug therapy are less robust. Therefore, this issue should also be addressed by further investigations.

Comparison of changes (Δ) in each parameter between higher and lower groups of serum s(P)RR concentration {#sec020}
---------------------------------------------------------------------------------------------------------

In our study, in patients who survived, ΔhANP and ΔBNP levels and ΔIVST were significantly higher in patients with serum s(P)RR ≥29.8 ng/ml than in those with s(P)RR \<29.8 ng/ml ([Table 4](#pone.0233312.t004){ref-type="table"}, [Fig 1](#pone.0233312.g001){ref-type="fig"}), suggesting that a status of higher serum s(P)RR is related to aggravation of cardiac hypertrophy and heart failure.

We have reported that the long-term administration of a (P)RR blocker attenuated the development of cardiac fibrosis and hypertrophy \[[@pone.0233312.ref028]\]. These findings raise the possibility that the activation of (P)RR in the heart may contribute to cardiac fibrosis and hypertrophy in HD patients, and further studies are needed to address this issue.

Relationships between ΔBNP and serum s(P)RR levels {#sec021}
--------------------------------------------------

In our study, an association between high Δ BNP and the group with higher s(P)RR was observed even after correction for LDL-C, TG, hANP, and BNP, which were correlated with the ΔBNP level (Tables [5](#pone.0233312.t005){ref-type="table"} and [6](#pone.0233312.t006){ref-type="table"}). These data indicate the possibility that an increased expression of (P)RR in the heart may cause worsening of heart failure independent of other Δ BNP-related factors at the start time of observation. They also suggest that serum s(P)RR concentration could be used as a biomarker for the progression of heart failure and thus may be useful in selecting patients who require more intensive care in terms of heart failure.

Limitations {#sec022}
===========

We should acknowledge that there are some limitations to this study. Firstly, our sample size was relatively small. Secondly, the present data of HD patients may have been modulated by HD therapy, because s(P)RR is dialyzed to some extent^11^. Thirdly, the mechanisms by which serum s(P)RR level is associated with background factors remain unclear. Fourthly, the causal relationship between high serum s(P)RR level and high Δ BNP remains undetermined. Further studies are required to clarify the role of serum s(P)RR level in HD patients in more detail.

Conclusions {#sec023}
===========

High serum s(P)RR level in HD patients was associated with various background factors and several changes in cardiac function and atherogenic factors. Furthermore, high serum s(P)RR level was independently correlated with Δ BNP after correction for other Δ BNP-related factors. It may be possible that s(P)RR can be used as a marker of progression of heart failure in HD patients. Further studies are needed to determine the prognostic significance of serum s(P)RR concentration in HD patients and whether reducing serum s(P)RR level may improve the prognoses of these patients.
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Comments to Reviewer \#1:

Thank you very much for your excellent comments.

1)Your comment:

This reviewer strongly recommends to reconstruct the Introduction. First of all, any general knowledge about PRR and HD/CVD should be removed. Then, the authors should clearly mention what is known and what is not known about sPRR, especially for CKD/CVD. As you know, there are many reports that sPRR is a good biomarker for CKD/CVD, except references \#11 and 30. Finally, rational of this study and specific hypothesis should be mentioned.

\>\>\> Our comment:

Following your suggestion, we revised the Introduction by removing general knowledge about (P)RR and HD/CVD, by describing what is known and unknow about s(P)RR in HD patients, and by showing our hypothesis.

2\) Your comment:

Similarly, discussion should focus on the obtained data. Any introduction and general knowledge about PRR and HD/CVD should be removed.

\>\>\> Our comment:

Following your suggestion, we removed parts describing general knowledge about PRR and HD/CVD which reads: "Systemic inflammation is common in HD patients, and CRP is released from hepatocytes in response to inflammation. Elevated serum CRP is a strong predictor of mortality, and higher CRP levels are associated with worse outcomes in HD patients. Protein energy wasting is a state of decreased body stores of protein and energy fuel and is associated with diminished functional capacity, impaired quality of life, and increased morbidity and mortality in HD patients. It has also been reported that malnutrition is the most important factor associated with increased mortality in HD patients. Although it remains unclear whether malnutrition directly causes mortality or is a result of diseases that cause mortality" (L.4 to L.12, P.24 in the Revised Manuscript with Track Changes), "A previous report demonstrated that gene expressions of (P)RR, renin, and angiotensinogen were elevated in the heart and kidneys of rats with chronic heart failure. It has been reported that patients with heart failure had significantly higher plasma s(P)RR levels than control subjects. Local (P)RR gene delivery into the heart showed deleterious effects on cardiac function via activation of angiotensin II-independent extracellular matrix remodeling. Cardiac-specific overexpression of (P)RR was shown to cause both electronic remodeling and structural remodeling in the atria by activation of the angiotensin II-independent pathway and eventually led to atrial fibrillation. High salt intake enhanced the cardiac expressions of (P)RR, leading to the acceleration of cardiac interstitial fibrosis, perivascular fibrosis, and cardiomyocyte hypertrophy via angiotensin II-dependent and -independent pathways at an early stage of hypertension" (L.14, P.26 to L.8, P.27 in the Revised Manuscript with Track Changes), and "There are several reports demonstrating that BNP level is particularly useful for diagnosing heart failure, evaluating heart failure severity, and predicting cardiovascular events and risk of death in HD patients" (L.15 to 17, P. 27 in the Revised Manuscript with Track Changes).

3\) Your comment:

The authors should discuss why basal sPRR levels are different among the reports.

\>\>\> Our comment:

Thank you very much for your valuable comment. Following your suggestion, we discussed why basal s(P)RR levels are different among the reports as follows: "It has been shown that basal blood s(P)RR levels differ among reports with a tendency of blood s(P)RR levels to be high in older subjects \[4, 20\], patients with heart failure \[7\], renal dysfunction \[21\], or Graves' disease \[22\], and pregnant women \[23, 24\]. The reason of the alterations of these values may be due to the differences of the disease and conditions of the subjects \[24\]. Our study subjects undergoing maintenance HD also showed high serum s(P)RR levels, which were significantly higher when compared with subjects with normal renal function \[8\]. Although the reason for this remains unclear, there are several possible explanations. First, elevated serum s(P)RR levels may reflect an increase in expression of (P)RR in the kidneys. Second, increased expression of (P)RR in other organs such as the heart and brain, where the expression levels of (P)RR are extremely high \[1\], may be the cause of elevated serum s(P)RR level. Third, elevated serum s(P)RR levels may be simply due to a decrease or loss of excretion from the kidney" (L. 4 to 16, P.22 in the Revised Manuscript with Track Changes).

4\) Your comment:

Is there any difference between diabetic and nondiabetic patients?

\>\>\> Our comment:

Thank you very much for excellent comment. We added data about diabetes in Tables 1 and 2. We also revised the Results as follows: "Primary disease (diabetic or not) was not significantly different between the 2 groups" (L.8 to 9, P.11 in the Revised Manuscript with Track Changes) and "No significant differences in primary disease (DM/no DM) was noted between in the survival and death groups" (L.1 to 2, P.14 in the Revised Manuscript with Track Changes).

 

Comments to Reviewer \#2:

Thank you very much for your excellent comments.

1)Your comment:

The mechanistic explanation of s(P)RR in hemodialysis is missing. Where does the blood s(P)RR is secreted in hemodialysis patients?

\>\>\> Our comment:

Thank you very much for your valuable comment. We discussed why serum s(P)RR levels are increased in HD patients as follows: "Our study subjects undergoing maintenance HD also showed high serum s(P)RR levels, which were significantly higher when compared with subjects with normal renal function \[8\]. Although the reason for this remains unclear, there are several possible explanations. First, elevated serum s(P)RR levels may reflect an increase in expression of (P)RR in the kidneys. Second, increased expression of (P)RR in other organs such as the heart and brain, where the expression levels of (P)RR are extremely high \[1\], may be the cause of elevated serum s(P)RR level. Third, elevated serum s(P)RR levels may be simply due to a decrease or loss of excretion from the kidney" (L.8 to 16, P.22 in the Revised Manuscript with Track Changes).

2)Your comment:

The background of the medication should be provided and discuss whether these have influenced to the results.

\>\>\> Our comment:

Thank you for your excellent comment. Following your suggestion, we added data of selected medication in Tables 1, 2, and 5. We found that the selected medication influenced the data of serum s(P)RR and prognosis but not ΔBNP, the most important part of this study. We revised the Materials and Methods as follows: "At the start of this study, we collected information on the study population, including age, sex, body mass index (BMI), primary disease (diabetic or not), duration of HD, smoking status, and selected medication" (L.9 to 11, P.6 in the Revised Manuscript with Track Changes). And we corrected Results as follows: "With respect to antihypertensive treatment, the ratio of patients taking RAS-inhibitors (RAS-Is), such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), and renin inhibitors, was significantly higher in the lower serum s(P)RR group (83.7 %) than in the higher serum s(P)RR group (69.0 %)" (L.4 to 8, P.11 in the Revised Manuscript with Track Changes), and "With respect to antihypertensive treatment, the ratio of taking RAS-Is and calcium channel blockers (CCBs) were significantly higher in the survival group (79.4 % and 77.3 %, respectively) than the death group (45.8 % and 41.7 %, respectively)" (L.15 to 18, P.13 in the Revised Manuscript with Track Changes), and "The ratio of patients taking RAS-Is, β-blockers, and CCBs did not show significant relationship with ΔBNP" (L.2 to 5, P.14 in the Revised Manuscript with Track Changes). In addition, we revised Discussion: "In our study, the patients in the lower serum s(P)RR group took RAS-Is more frequently than those in the higher serum s(P)RR group (Table 1). It has been reported that a significantly lower level of serum s(P)RR was observed in CKD patients treated with ARBs \[21\], consistent with our study" (L.16, P. 23 to L. 1, P. 24 in the Revised Manuscript with Track Changes), and "In this study, the ratio of patients taking RAS-Is and CCBs was higher in the survival group than in the death group (Table 2). Because our sample size was relatively small and most patients were taking both RAS-Is and CCBs, statistical group comparisons between patients with and without antihypertensive drug therapy are less robust. Therefore, this issue should also be addressed by further investigations" (L.4 to 8, P.26 in the Revised Manuscript with Track Changes).

3)Your comment:

The association plot between delta BNP and s(P)RR should be figured.

\>\>\> Our comment:

Following your suggestion, we made an association plot between serum s(P)RR level and ΔBNP (Supplemental Figure 1). In line with the result showing no significant relationship between serum s(P)RR level and ΔBNP as a whole (Table 5), the figure was not good enough to show a strong relationship between serum s(P)RR level and ΔBNP. However, when the subjects were divided into the higher and lower s(P)RR groups, ΔBNP was significantly higher in the higher s(P)RR group than in the lower s(P)RR group as already shown in Table 4)." We added this explanation in Results as follows instead of showing the Supplemental Figure 1: "Serum s(P)RR level was not associated with ΔBNP level (Table 5). On the other hand, when the subjects were divided into the higher and lower s(P)RR groups, ΔBNP was significantly higher in the higher s(P)RR group than in the lower s(P)RR group (Figure 1)" (L.11 to 14, P.19 in the Revised Manuscript with Track Changes).

3)Your comment:

Did hemodialysis parameters such as dry weight, Qb, Qd and types of dialyzer influenced the results. Please provide and discuss.

\>\>\> Our comment:

Thank you very much for your valuable comment. As an index of body weight, we assessed BMI instead of dry weight which may not reflect the actual body weight and we found that BMI was not associated with serum s(P)RR level at baseline (Table 1). Qb, Qd, and types of dialyzer may affect the hemodialysis efficiency. We assessed Kt/V instead of Qb, Qd, and types of dialyzer, because Kt/V is considered to be a better index of hemodialysis efficiency. And as a result, we found that Kt/V was not significantly different between higher and lower groups of serum s(P)RR concentration (revised Table 1) and between survival and death groups (revised Table 2) and that there was no relationship between Kt/V and ΔBNP level (revised Table 5).

We added data of Kt/V in Tables 1, 2, and 5. In addition, we revised the Materials and Methods as follows: "The Kt/V was calculated on the 1st dialysis day of the week using the following equation, the formula of Daugirdas \[9\]: Kt/V = - Ln \[post-dialysis value of BUN / pre-dialysis value of BUN - 0.008 x dialysis time\] + (4 - 3.5 x post-dialysis value of BUN / pre-dialysis value of BUN) x amount of drainage / post-dialysis body weight}" (L.14 to 17, P. 6 in the Revised Manuscript with Track Changes). In addition, we revised the Results as follows: "In addition, neither BMI nor Kt/V was significantly different between the 2 groups, suggesting that hemodialysis parameters may not have strong influences on the serum s(P)RR levels" (L.9 to 11, P.11 in the Revised Manuscript with Track Changes).

10.1371/journal.pone.0233312.r003
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